EUCTR2015-001718-80-IT进行中（未招募）1 期
A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF) - PRM-151G-101
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 124
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subjects must be =18 years of age at the time of signing the Informed Consent Form (ICF);
- •2. Subjects must voluntarily sign an ICF;
- •3. Subjects must have a pathologically confirmed diagnosis of PMF as per the WHO diagnostic criteria or post ET/PV MF;
- •4. At least Grade 2 marrow fibrosis according to the WHO Grading of Bone Marrow Fibrosis;
- •5. Intermediate-1, intermediate -2, or high risk disease according to the IWG-MRT Dynamic International Prognostic Scoring System;
- •6. A bone marrow biopsy must be performed within four weeks prior to Cycle 1 Day 1 treatment to establish the baseline fibrosis score;
- •7. Subjects must not be candidates for ruxolitinib based on EITHER: a.Platelet count < 50 x 10^9/L, OR b. Hgb < 100 g/L, have received = 2 units PRBC in the 12 weeks prior to study entry, and be intolerant of or had inadequate response to ruxolitinib;
- •8. Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.
- •9. Life expectancy of at least twelve months;
- •10. At least four weeks must have elapsed between the last dose of any MF-directed drug treatments for myelofibrosis (including investigational therapies) and study enrollment;
- •11. Recovery to = Grade 1 or baseline of any toxicities due to prior systemic treatments, excluding alopecia;
- •12.Women of child bearing potential (WCBP), defined as a sexually mature woman not surgically sterilized or not post-menopausal for at least 24 consecutive months if < 55 years or 12 months if > 55 years, must have a negative serum pregnancy test within four weeks prior to the first dose of study drug and must agree to use highly effective methods of birth control throughout the study.Highly effective methods of contraception include combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation by oral, intravaginal, or transdermal administration; progestogen-only hormonal contraception associated with inhibition of ovulation by oral, injectable, or implantable administration; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; partner vasectomy, and total abstinence (only if total abstinence is the preferred method and usual lifestyle of thesubject). Adequate contraceptive use should be continued until 28 days after the final dose of the study drug.
- •13. Ability to adhere to the study visit schedule and all protocol requirements;
- •14. Must have adequate organ function as demonstrated by the following: • ALT (SGPT) and/or AST (SGOT) = 3x upper limit of normal (ULN), or = 4 x ULN (if upon judgment of the treating physician, it is
- •believed to be due to extramedullary hematopoiesis [EMH] related to MF); • Direct bilirubin = 1.5 x ULN; or = 2x ULN (if upon judgment of the treating physician, it is believed to be due to EMH related to MF); •Serum creatinine = 2.5 x ULN.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 42
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 42
排除标准
- •1. White blood cell count > 25 x 10^9/L or > 10% peripheral blood blasts;
- •2. Other invasive malignancies within the last 3 years, except nonmelanoma skin cancer and localized cured prostate and cervical cancer;
- •3. History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months;
- •4. Presence of active serious infection;
- •5. Any serious, unstable medical or psychiatric condition that would prevent, (as judged by the Investigator) the subject from signing the informed consent form or any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk ifhe/she were to participate in the study or confounds the ability to interpret data from the study;
- •6. Known history of human immunodeficiency virus (HIV), or known active hepatitis A, B, or C infection;
- •7. Organ transplant recipients other than bone marrow transplant;
- •8. Women who are pregnant or lactating.
研究者
相似试验
已完成
2 期
A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF)myelofibrosebone marrow replaced by scarMyelofibrosisNL-OMON44095Promedior, Inc10
进行中（未招募）
1 期
A study to test intravenous PRM-151 to see how different doses of PRM-151 act in the body and blood of people with myelofibrosis - a disorder of the bone marrow, in which the marrow is replaced by scar (fibrous) tissue.EUCTR2015-001718-80-FRPromedior, Inc84
进行中（未招募）
1 期
A study to test intravenous PRM-151 to see how different doses of PRM-151 act in the body and blood of people with myelofibrosis - a disorder of the bone marrow, in which the marrow is replaced by scar (fibrous) tissue.Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF)MedDRA version: 21.0 Level: LLT Classification code 10074689 Term: Post polycythemia vera myelofibrosis System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0 Level: LLT Classification code 10074690 Term: Post essential thrombocythemia myelofibrosis System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10028537 Term: Myelofibrosis System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-001718-80-DEPromedior, Inc84
进行中（未招募）
1 期
A study to test intravenous PRM-151 to see how different doses of PRM-151 act in the body and blood of people with myelofibrosis - a disorder of the bone marrow, in which the marrow is replaced by scar (fibrous) tissue.Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF)MedDRA version: 21.0Level: LLTClassification code 10074689Term: Post polycythemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074690Term: Post essential thrombocythemia myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-001718-80-NLPromedior, Inc98
已完成
2 期
A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)IPFlung fibrosis10024967NL-OMON43714Promedior, Inc21